Eupraxia Pharmaceuticals is trading at $7.11, up 5.18% in after-hours trading; no verified company announcement on November 2 was found to explain the rise.
- Q3 2026 results are expected November 3; the reported date is an estimate, and the consensus EPS forecast is -$0.26.
- The RESOLVE enrollment milestone was announced October 15, with interim data expected in December; it is prior context, not a confirmed new catalyst.
- After-hours volume or activity data was unavailable.